The FDA's medical reviewer's recommendation for approval says, in part, that more trials before approval would «significantly delay
effective therapy,» which not only reduces body weight but exerts favorable effects on blood
pressure and myocardial
oxygen for «patients with a serious disease condition with few treatment options.»
Because radiation therapy requires the presence of
oxygen to be
effective, tumors with high interstitial
pressure are often less receptive to radiation therapy.